Antisocial behaviour and conduct disorders in children and young people: recognition and management

Evidence

We found 7 studies in a search for randomised controlled trials and systematic reviews published between 1 May 2015 and 8 November 2016.

We also considered evidence identified in previous surveillance 2 years after publication of the guideline. This included 15 studies identified by the 2‑year surveillance review.

From all sources, we considered 22 studies to be relevant to the guideline.

We also checked for relevant ongoing research, which will be evaluated again at the next surveillance review of the guideline.

See appendix A: summary of evidence from surveillance for details of all evidence considered, and references.

Views of topic experts

We considered the views of topic experts, including those who helped to develop the guideline and other correspondence we have received since the publication of the guideline.

Views of stakeholders

Stakeholders commented on the decision not to update the guideline. Overall, 2 stakeholders commented. See appendix B for stakeholders' comments and our responses.

Two stakeholders commented on the proposal to not update the guideline: 1 agreed with the decision and 1 disagreed with the decision. One stakeholder comment suggested that the guideline should address fetal alcohol spectrum disorder, pharmacological interventions for people with coexisting learning disabilities, populations in contact with the criminal justice system and restrictive practices. The areas highlighted in the comments were included in the guideline. Current recommendations advise on conducting a comprehensive assessment for case identification and include assessment of alcohol use during pregnancy. Similarly, the guideline recommends interventions when children and young people aged between 3 and 11 years are in contact with the criminal justice system because of antisocial behaviour. Although children with coexisting learning disabilities are included within the scope of this guideline, other more relevant guidelines cover pharmacological treatments in detail for this population (see the NICE guideline on mental health problems in people with learning disabilities). Although no evidence was found to impact on the guideline at this time, these areas will be considered again at the next surveillance review of NICE guideline CG158.

We requested stakeholders to comment on the removal of 5 priority research recommendations. One stakeholder disagreed with the proposal to remove the research recommendation about the effectiveness of parent training programmes. Having considered the views of stakeholders, this research recommendation will now be retained and considered again at the next surveillance review of NICE guideline CG158. No further responses were received for any of the other research recommendations.

Stakeholders were requested to comment on areas excluded from the scope of the guideline and any equalities issues. No comments on equalities issues were made by stakeholders during consultation.

Overall, we decided not to update the guideline.

See ensuring that published guidelines are current and accurate in developing NICE guidelines: the manual for more details on our consultation processes.

NICE Surveillance programme project team

Kay Nolan
Associate Director

Philip Alderson
Consultant Clinical Adviser

Emma McFarlane
Technical Adviser

Omar Moreea
Technical Analyst

The NICE project team would like to thank the topic experts who participated in the surveillance process.

ISBN: 978-1-4731-2445-5